Background: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is often found with distinct pancreatic ductal adenocarcinoma (PDAC) in the same pancreas. The aim of this study was to clarify whether endoscopic retrograde pancreatography (ERP) would be useful for the early detection of concomitant PDACs in patients with IPMNs.
Methods: Medical records of 179 patients who were histologically confirmed to have IPMNs after resection between 1987 and 2011 were reviewed. The patients having concomitant PDACs were selected, and the diagnostic abilities to detect concomitant PDACs of computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and ERP were compared between early (stages 0-I according to Japanese General Rules for Pancreatic Cancer) and advanced (stages II-IV) PDACs.
Results: A total of 23 PDACs developed synchronously or metachronously in 20 patients, and the prevalence of PDACs concomitant with IPMNs was 11.2 % (20/179). Sensitivities of CT (16 vs. 87 %), MRI (29 vs. 93 %), and EUS (29 vs. 92 %) in the early group were significantly lower than those in the advanced group (p < 0.01). On the other hand, the sensitivity of ERP in the early group was as high as that in the advanced group (86 vs. 82 %, respectively, p > 0.99). Among 7 early PDACs, 3 were diagnosed only by ERP.
Conclusions: ERP has an important role in the early diagnosis of distinct PDACs in patients with IPMNs. Further investigation is necessary to clarify the indication and the timing of ERP during management of IPMNs in term of early detection of concomitant PDACs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00534-012-0541-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraductal Papillary Mucinous Neoplasm Surveillance Leads to Early Diagnosis and Better Outcomes of Concomitant Cancer.
Ann Surg
March 2024
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- The study investigated whether long-term monitoring of intraductal papillary mucinous neoplasms (IPMNs) results in earlier detection and improved outcomes for pancreatic ductal adenocarcinomas (PDACs) that develop alongside IPMNs.
- Out of 4,620 patients with pancreatic cysts, 63 developed PDAC during surveillance, and their overall survival (OS) was compared to 460 patients with non-IPMN-associated PDACs.
- Results showed that patients with concomitant PDACs were diagnosed at earlier cancer stages and had a significantly longer OS and higher 5-year survival rates compared to those with non-IPMN-associated PDACs.
Pancreatic ductal adenocarcinomas concomitant with intraductal papillary mucinous neoplasms of the pancreas: A investigation of those clinicopathological features by analyzing 48 patients who underwent surgery for those lesions.
Pancreatology
September 2023
Department of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Background: Differences between pancreatic ductal adenocarcinomas (PDACs) concomitant with intraductal papillary mucinous neoplasm (IPMN) (C-PDACs), those without IPMN (NC-PDACs) and invasive cancers derived from IPMN (IC-Ds) have not been fully clarified.
Methods: Forty-eight patients with C-PDAC were included to investigate the differences in 1) clinicopathological features and 2) post-operative courses among the three invasive cancer groups.
Results: 1) Characteristics of C-PDACs were mostly similar to those of NC-PDACs; whereas, between C-PDACs and IC-Ds, the rate of mucinous carcinoma (2%/25%, p = 0.
Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms.
BMC Gastroenterol
December 2022
Department of Gastroenterology, Kure Medical Center and Chugoku Cancer Center, 737-0023, Aoyamacho 3-1, Kure, Hiroshima, Japan.
Background: When monitoring patients with an intraductal papillary mucinous neoplasm (IPMN), it is important to consider both IPMN-derived carcinoma and concomitant ductal adenocarcinoma (PDAC). The latter is thought to have a poorer prognosis. We retrospectively analyzed the risk factors for concomitant PDAC in IPMN.
View Article and Find Full Text PDFCytomorphological and immunohistochemical features of pancreatic ductal adenocarcinoma in serous fluids.
Diagn Cytopathol
October 2022
Department of Pathology, Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background: Pancreatic ductal adenocarcinoma (PDAC) represents the most common primary pancreatic malignancy. An understanding of the cytomorphologic features of conventional ductal adenocarcinoma and its variants is important to ensure accurate diagnoses.
Methods: The clinicopathological and cytological data of serous fluids in PDAC patients were obtained from the electronic medical records and pathology database.
Pancreatic Ductal Adenocarcinoma Concomitant with Main Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Case Report.
Am J Case Rep
September 2021
Department of Gastroenterology, Sendai City Medical Center, Sendai, Miyagi, Japan.
BACKGROUND Intraductal papillary mucinous neoplasm of the pancreas (IPMN) and pancreatic ductal adenocarcinoma (PDAC) often coexist in the same pancreas. Almost all IPMNs involving PDACs concomitant with IPMN have been shown to be branch duct type IPMNs (BD-IPMNs), and their histological subtypes are gastric type. Therefore, PDACs concomitant with main duct type IPMNs (MD-IPMNs) are considered to be rare.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!